135 related articles for article (PubMed ID: 16736568)
1. Advances in adjuvant therapy for breast cancer.
Slamon DJ; Romond EH; Perez EA;
Clin Adv Hematol Oncol; 2006 Mar; 4(3 Suppl 7):suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10. PubMed ID: 16736568
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy for breast cancer.
Hennessy BT; Pusztai L
Minerva Ginecol; 2005 Jun; 57(3):305-26. PubMed ID: 16166938
[TBL] [Abstract][Full Text] [Related]
3. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
[TBL] [Abstract][Full Text] [Related]
4. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Andersson M; Kamby C
Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
[TBL] [Abstract][Full Text] [Related]
5. Integration of novel targeted therapies into the systemic treatment of breast cancer--a review.
Tsakonas G; Kosmas C
J BUON; 2007; 12(3):319-27. PubMed ID: 17918284
[TBL] [Abstract][Full Text] [Related]
6. Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy.
Yonemori K; Katsumata N; Kaneko M; Uno H; Matsumoto K; Kouno T; Shimizu C; Ando M; Takeuchi M; Fujiwara Y
Breast Cancer Res Treat; 2007 Jul; 103(3):313-8. PubMed ID: 17063267
[TBL] [Abstract][Full Text] [Related]
7. Target-based therapies in breast cancer: current status and future perspectives.
Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more?
Oakman C; Pestrin M; Cantisani E; Licitra S; DeStefanis M; Biganzoli L; Di Leo A
Breast; 2009 Oct; 18 Suppl 3():S18-24. PubMed ID: 19914536
[TBL] [Abstract][Full Text] [Related]
11. First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment.
Morabito A; Piccirillo MC; Monaco K; Pacilio C; Nuzzo F; Chiodini P; Gallo C; de Matteis A; Perrone F;
Oncologist; 2007 Nov; 12(11):1288-98. PubMed ID: 18055848
[TBL] [Abstract][Full Text] [Related]
12. New drugs for breast cancer.
Tookman L; Roylance R
Br Med Bull; 2010; 96():111-29. PubMed ID: 20870669
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy for metastatic breast cancer.
Nabholtz JM; Reese DM; Lindsay MA; Riva A
Expert Rev Anticancer Ther; 2002 Apr; 2(2):169-80. PubMed ID: 12113239
[TBL] [Abstract][Full Text] [Related]
14. Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer.
Albain KS; Carey L; Gradishar WJ; Gralow JR; Lipton A; Rugo H; Tripathy D; Peck S; Abair T; Pegram M
Clin Breast Cancer; 2010 Dec; 10(6):421-39. PubMed ID: 21147685
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic therapies in breast cancer.
Sarmiento R; D'Andrea MR; Cacciamani F; Salerno F; Gasparini G
Curr Opin Investig Drugs; 2009 Dec; 10(12):1334-45. PubMed ID: 19943205
[TBL] [Abstract][Full Text] [Related]
16. Targeted cancer therapies.
Blay JY; Le Cesne A; Alberti L; Ray-Coquart I
Bull Cancer; 2005 Feb; 92(2):E13-8. PubMed ID: 15749638
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the use of chemotherapy in breast cancer.
Nabholtz JM; Reese D; Lindsay MA; Riva A
Int J Clin Oncol; 2002 Aug; 7(4):254-64. PubMed ID: 12202979
[TBL] [Abstract][Full Text] [Related]
18. Extending survival with chemotherapy in metastatic breast cancer.
O'Shaughnessy J
Oncologist; 2005; 10 Suppl 3():20-9. PubMed ID: 16368868
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy: updates and new perspectives.
Swain SM
Oncologist; 2010; 15 Suppl 5():8-17. PubMed ID: 21138951
[TBL] [Abstract][Full Text] [Related]
20. What can be expected from the next generation of adjuvant breast cancer treatment?
Piccart-Gebhart M
Semin Oncol; 1999 Feb; 26(1 Suppl 3):22-5. PubMed ID: 10203267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
